United States Patent 7,271,238: A Detailed Analysis of Scope and Claims
Introduction
United States Patent 7,271,238, titled "Amylin agonist peptides and uses therefor," is a significant patent in the field of pharmaceuticals, particularly focusing on peptides related to amylin, a hormone involved in glucose regulation. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background of the Invention
Amylin is a peptide hormone co-secreted with insulin from the pancreas and plays a crucial role in glucose homeostasis. The patent addresses the need for amylin agonist peptides that can be used to treat conditions such as diabetes and obesity[4].
Summary of the Invention
The patent describes amylin agonist peptides and their uses, particularly in the treatment of metabolic disorders. These peptides are designed to mimic the natural action of amylin, enhancing its therapeutic benefits while potentially reducing side effects.
Claims of the Patent
The patent includes several key claims that define the scope of the invention:
Composition of Matter Claims
These claims cover the specific amylin agonist peptides, including their amino acid sequences and any modifications that enhance their stability or efficacy. For example, the patent specifies peptides with particular sequences that exhibit high affinity for the amylin receptor[4].
Method of Use Claims
These claims outline the therapeutic uses of the amylin agonist peptides, such as treating diabetes, obesity, and other metabolic disorders. The methods include administration routes, dosages, and treatment regimens[4].
Pharmaceutical Compositions Claims
The patent also claims pharmaceutical compositions that include the amylin agonist peptides, along with other components like excipients, stabilizers, and delivery systems. These compositions are designed to improve the bioavailability and stability of the peptides[4].
Scope of the Patent
The scope of the patent is defined by the breadth of its claims and the specific embodiments described.
Breadth of Claims
The claims are structured to cover a range of amylin agonist peptides, including variations in their sequences and modifications. This breadth ensures that the patent protects not only the specific peptides described but also related peptides that might be developed in the future[4].
Specific Embodiments
The patent provides detailed descriptions of specific peptides, their synthesis methods, and their pharmacological properties. These embodiments serve as examples of how the invention can be practiced and help to define the limits of the claims[4].
Patent Landscape
Understanding the patent landscape around U.S. Patent 7,271,238 involves looking at related patents, licensing agreements, and the overall competitive environment.
Related Patents
Other patents related to amylin and its agonists include those focusing on different aspects such as delivery systems, combination therapies, and novel peptide sequences. For example, patents like those described in the Justia Patents database cover a wide range of biologically active proteins and their applications[1][5].
Licensing Agreements
Licensing agreements, such as those between pharmaceutical companies, can impact the commercialization and use of the patented peptides. These agreements often define the terms under which the patented technology can be used, including royalties, territorial rights, and exclusivity periods[2].
Competitive Environment
The competitive environment in the pharmaceutical industry, particularly in the area of metabolic disorder treatments, is highly dynamic. Other companies and research institutions are continually developing new treatments, which can affect the market position and value of the patented peptides[4].
Impact on Innovation
The patent's impact on innovation is multifaceted:
Encouraging Research and Development
By providing exclusive rights to the inventors, the patent incentivizes further research and development in the field of amylin agonists. This can lead to improved treatments and new therapeutic applications[3].
Licensing and Collaboration
The patent can facilitate licensing agreements and collaborations between different entities, promoting the sharing of knowledge and resources. This collaboration can accelerate the development and commercialization of new treatments[2].
Litigation and Licensing Costs
However, the patent can also increase litigation and licensing costs, potentially hindering innovation if the claims are overly broad or if there are disputes over patent validity. Narrower claims, as suggested by research on patent scope, can mitigate these issues[3].
Key Takeaways
- Specific Claims: The patent includes detailed claims on the composition of matter, methods of use, and pharmaceutical compositions of amylin agonist peptides.
- Scope and Breadth: The scope is defined by the breadth of claims and specific embodiments, ensuring protection for a range of related peptides.
- Patent Landscape: The patent is part of a larger landscape involving related patents, licensing agreements, and a competitive environment in the pharmaceutical industry.
- Impact on Innovation: The patent incentivizes research and development but can also increase costs related to litigation and licensing.
FAQs
-
What is the primary focus of U.S. Patent 7,271,238?
- The primary focus is on amylin agonist peptides and their therapeutic uses, particularly in treating metabolic disorders like diabetes and obesity.
-
What types of claims are included in the patent?
- The patent includes composition of matter claims, method of use claims, and pharmaceutical composition claims.
-
How does the patent impact innovation in the pharmaceutical industry?
- It incentivizes research and development by providing exclusive rights but can also increase costs related to litigation and licensing.
-
What is the significance of the patent landscape around U.S. Patent 7,271,238?
- The patent landscape includes related patents, licensing agreements, and a competitive environment that can affect the commercialization and value of the patented peptides.
-
How can narrower claims affect the patent's impact on innovation?
- Narrower claims can reduce litigation and licensing costs, making it easier for other innovators to build upon the patented technology without infringing on the patent.
Citations
[4] https://pubchem.ncbi.nlm.nih.gov/patent/US-7271238-B2
[1] https://patents.justia.com/patent/10961287
[2] https://www.sec.gov/files/18-03444-e.pdf
[3] https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
[5] https://patents.justia.com/patent/10934572
